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Letters to the Editor
Progesterone receptor gene polymorphism and risk for
breast and ovarian cancer
Sir,
McKenna et al (March, 1995) used Southern analysis to identify a
germline TaqI restriction fragment length polymorphism (RFLP)
in intron G of the human progesterone receptor (hPR) defined by
two alleles, TI and T2. The T2 allele contained an additional TaqI
restriction site relative to TI, and was recently characterized as a
306 bp Alu element insertion and named PROGINS (Rowe et al,
1995). No functional consequences of this intronic insertion have
been reported, but McKenna et al (1995) suggested that the T2
allele is over-represented in patients with ovarian carcinoma.
Twenty-four out of 67 (36%) German and Irish patients with
ovarian cancer were homozygous or heterozygous for the T2
allele, in contrast to only 38 out of 184 (21%) control subjects.
To investigate this association in a Caucasian North-American
population, we designed a PCR-based assay using forward (5'-
GGC AGA AAG CAA AAT AAA AAG A-3') and reverse (5'-
AAA GTA TTT TCT TGC TAA ATG TC-3') primers to amplify
the region spanning the insertion. Leucocyte DNA was analysed
Table 1 Distribution of hPR polymorphism in control, ovarian, and breast
cancer groups
Ti/Ti (%) T1/T2 (%) T2/T2 (%)
Control (n= 101) 79(78) 18 (18) 4 (4)
Ovarian cancer (n = 96) 76 (79) 15 (16) 5 (5)
Breastcancer(n= 68) 55(81) 12(18) 1 (1)
Ti/Ti, homozygotes without the 306-bp insertion; T1/T2, heterozygotes with
the insertion; T2/T2, homozygotes with the insertion.
from 96 patients with ovarian cancer and 68 patients with breast
cancer treated at Duke University Medical Center, Durham, NC,
USA, between 1985 and 1996, and 1O1 non-cancer female control
subjects enrolled through outpatient clinics at the same hospital.
The frequency of T2 genotypes in American control women is
similar to that of the pooled Irish/German control subjects.
However, we observe no increased frequency in women with
the T2 genotype among cases of breast or ovarian cancer relative
to controls subjects (Table 1), in contrast to the study by McKenna
et al (1995).
In the absence of data that the insertion of an Alu element in
intron G of the progesterone receptor gene has any consequences
for gene function, we find little support for the hypothesis that the
T2 allele increases risk for ovarian or breast cancer.
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Lymphagenesis and cancer metastasis
Sir,
A recent article by Ohta et al (1997) examines the relationship
between lung cancer metastasis and vascular endothelial growth
factor (VEGF) expression. The authors suggest that lymph node
metastasis may be enhanced by an increase in the number of
lymphatic vessels in the primary tumour. They referto this process as
'lymphogenesis'. Unfortunately, this term is often used to as a
reference to lymphocyte proliferation or, in some cases, lymph fluid
production and, thus, could be misleading in this context. We have
suggested the use ofthe term lymphagenesis to describe the process
of lymphatic vessel formation (Cann et al, 1995; van Netten et al,
1996). Another synonymous term, lymphangiogenesis, may be
confused with both vascular systems because angiogenesis, first used
by Hertig (1935), refers solely to blood vessel formation.
The majority of neovascular research in cancer has focused on
angiogenesis. This is partly because of the use of certain tech-
niques, such as corneal implantation or chorioallantoic membrane
assays, in which blood vessels can be clearly distinguished and
lymphatic vessels, although present, cannot. It is also because of
the use of so-called 'angiogenic' markers (i.e. von Willebrand
factor, CD31, CD34) that are not truly restricted to blood vessel
endothelium but that are also present on lymphatic vessels
(Miettinen et al, 1994; Appleton et al, 1996).
The process of lymphatic vessel development has gained
increasing attention with the discovery of a new VEGF receptor,
VEGFR3 (FLT4). VEGFR3 is expressed by lymphatic endothelial
cells, some high endothelial venules (Kaipainen et al, 1995) and
various tumour cell lines (Pajusola et al, 1992; Liu et al, 1997).
Enhanced expression has also been observed in murine hepatic
tumours (Karamysheva et al, 1996) and in lymph nodes containing
metastatic adenocarcinoma (Kaipainen et al, 1995). The ligand for
VEGFR3, VEGF-C, has been shown to be a specific inducer of
lymphatic endothelial cell proliferation and chemotaxis (Oh et al,
1997). Thus, lymphagenesis may be a more important factor in the
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